I have commented on GST policy, consumer prices, and medicine packaging, recording both my views and the policy changes I would like to see.
On online gaming GST, I wrote, “Gaming GST rules are turning into a potboiler 🙃”.
The post I shared reported that the GST Council meet was deferred on delay of GoM reports on online gaming, casinos and GST Appellate Tribunals; this was the quoted report, not my own reporting.
I called the color-coded explanation of 5% for essentials, 18% for standard goods, and 40% for super luxury & sin items a great way to explain the new GST regime.
I hoped that “2 slabs, and just maybe, one day, a single slab” would simplify life for consumers and businesses.
I said daily food-item prices were set to drop and predicted a 10% drop in prices across these food staples.
I said these categories see huge demand swings at 1% price movements.
My post did not identify the food categories, explain the basis for the figures, or give a timeframe for the predicted price drop.
I described visiting my local chemist for a 3-day course of medicine; the strip had 10 pills, I needed 6, and the chemist refused to cut it.
The chemist explained, “If I cut it, the next customer won’t buy it because they can’t see the expiry date.”
I said that in India, manufacturing and expiry details are usually printed in a single block on one end of a strip, and that cutting the strip loses the “source of truth.”
I said the Indian pharma industry’s domestic market grew to ₹2.4 lakh crore in 2025.
I said top companies enjoyed operating profit margins of 25% to 32%.
I said the industry was growing at 9-11% YoY.
I argued that packaging retooling should not be dismissed as too costly given the industry’s margins and growth, and that improving packaging is a basic requirement for patient safety and affordability.
I said Indian citizens are being forced to buy 40% more medicine than they need because printing standards have not been updated.
I said regulators (CDSCO) should mandate expiry and batch info be printed across every single blister cell, not just once per strip.
I proposed strips pre-perforated into single, fully-labeled units, so each pill could be bought with its own data.
I argued that pharma companies have the margins to absorb this transition and called for a move from “bulk-first” to “PATIENT-FIRST” packaging.
I presented these packaging approaches as common elsewhere but missing in India, and asked whether it was time for a mandate on unit-dose labelling. My post did not provide supporting citations or implementation details for the figures or proposals.
Related: consumption and tax policy, indian fashion and textiles, airfare and flight innovation